Table 4.

Comparisons of clinical characteristics of patients.

Characteristic	HAIC-courses≤3(n = 40)	HAIC-courses>3(n = 17)	TACE(n = 69)	P
gender
male	28	14	53	0.564
female	12	3	16
age
≤60	29	13	48	0.839
>60	11	4	21
Tumor size
≤5	4	1	5	0.829
>5	36	16	64
Vascular Invasion
Absence	18	10	34	0.634
Presence	22	7	35
LN metastasis
Absence	16	9	22	0.251
Presence	24	8	47
Distant metastasis
Absence	24	13	43	0.476
Presence	16	4	26
TNM stage
II	13	9	15	0.12
IIIb	11	4	27
IV	16	4	27
WBC (E+09)
≤10	28	12	50	0.96
>10	12	5	19
HGB (g/L)
≤120	11	3	18	0.723
>120	29	14	51
PLT (E+09)
≤300	30	15	56	0.494
>300	10	2	13
ALB (g/L)
≤40	20	4	34	0.135
>40	20	13	35
ALT (U/L)
≤50	32	11	56	0.322
>50	8	6	13
AST (U/L)
≤40	22	5	39	0.124
>40	18	12	30
ALP (U/L)
≤125	16	8	30	0.875
>125	24	9	39
GGT (U/L)
≤60	4	2	12	0.54
>60	36	15	57
TBIL (umol/L)
≤20.5	35	15	55	0.485
>20.5	5	2	14
IBIL (umol/L)
≤15	37	17	64	0.513
>15	3	0	5
CRP (ng/L)
≤3	4	3	7	0.654
>3	36	14	62
AFP (ng/ml)
≤25	25	13	42	0.483
>25	15	4	27
CEA (ng/mL)
≤5	21	13	46	0.147
>5	19	4	22
CA19-9 (U/ml)
≤35	12	5	24	0.809
>35	28	12	44
HBsAg
negative	17	7	30	0.974
positive	23	9	37
CA19-9 (U/ml)
≤200	24	14	40	0.171
>200	16	3	29
CA19-9effect
Negative before operation	10	5	14	0.952
Decline after operation	16	8	15
No decline after operation	7	4	8
PIVKA-II(mAU/ml)
≤40	23	11	20	0.269
>40	15	2	12